Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Senior VP, Finance and PAO | September 16, 2026 | September 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bolt Biotherapeutics, Inc.
Report date September 16, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,924 |
Reported balance
After 2026-06-05 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-06-05 · Purchase · Acquired 509 · Balance 1,924 F1: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 24,081 |
Reported balance
After 2026-09-16 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-09-16 · Sale · Disposed 843 · Balance 24,081 F2: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 21,159 |
Reported balance
After 2026-09-17 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-09-17 · Sale · Disposed 2,922 · Balance 21,159 F3: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 17,082 |
Reported balance
After 2026-09-18 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-09-18 · Sale · Disposed 4,077 · Balance 17,082 F4: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
F2: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 21, 2026 22:04 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | SaleCommon Stock | 4,077 | $3.24 | $13,194.80 |
DisclosureSEC source: 0001193125-26-396892 · ownership.xml · nonDerivative · entry 4 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,082 F4 · price: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 22:04 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | SaleCommon Stock | 2,922 | $3.32 | $9,696.07 |
DisclosureSEC source: 0001193125-26-396892 · ownership.xml · nonDerivative · entry 3 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,159 F3 · price: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 16, 2026 Filed Sep 21, 2026 22:04 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | SaleCommon Stock | 843 | $3.77 | $3,181.48 |
DisclosureSEC source: 0001193125-26-396892 · ownership.xml · nonDerivative · entry 2 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,081 F2 · price: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2026 Filed Sep 21, 2026 22:04 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 509 | $3.88 | $1,972.88 |
DisclosureSEC source: 0001193125-26-396892 · ownership.xml · nonDerivative · entry 1 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,924 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c). Read SEC document |
| January 28, 2026 Filed Feb 4, 2026 16:32 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $6.71 | $0.00 |
DisclosureSEC source: 0001193125-26-037690 · ownership.xml · derivative · entry 2 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2036-01-27 F2 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2026. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 11,299 | Not disclosed Strike: $7.02 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 18 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,299 shares Expires 2035-04-30 F13 · price: The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price. F12 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 11,299 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 17 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,299 Underlying: Common Stock · 11,299 shares Expires 2035-04-30 F13 · price: The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price. F12 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 4,499 | Not disclosed Strike: $14.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 16 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,499 shares Expires 2034-07-22 F11 · price: The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,499 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 15 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,499 Underlying: Common Stock · 4,499 shares Expires 2034-07-22 F11 · price: The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 2,499 | Not disclosed Strike: $14.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 14 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,499 shares Expires 2034-07-22 F11 · price: The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price. F10 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,499 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 13 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,499 Underlying: Common Stock · 2,499 shares Expires 2034-07-22 F11 · price: The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price. F10 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 1,589 | Not disclosed Strike: $25.40 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 12 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,589 shares Expires 2034-03-03 F9 · price: The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price. F8 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,589 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 11 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,589 Underlying: Common Stock · 1,589 shares Expires 2034-03-03 F9 · price: The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price. F8 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 6,699 | Not disclosed Strike: $27.80 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 10 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,699 shares Expires 2033-01-18 F7 · price: The reporting person agreed to cancellation of an option granted on January 19, 2023, in exchange for a new option having a lower exercise price. F6 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,699 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 9 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,699 Underlying: Common Stock · 6,699 shares Expires 2033-01-18 F7 · price: The reporting person agreed to cancellation of an option granted on January 19, 2023, in exchange for a new option having a lower exercise price. F6 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 2,199 | Not disclosed Strike: $61.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 8 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,199 shares Expires 2032-02-17 F5 · price: The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,199 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 7 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,199 Underlying: Common Stock · 2,199 shares Expires 2032-02-17 F5 · price: The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 600 | Not disclosed Strike: $90.20 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 6 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600 shares Expires 2031-12-21 F4 · price: The reporting person agreed to cancellation of an option granted on December 22, 2021, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 600 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 5 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 600 shares Expires 2031-12-21 F4 · price: The reporting person agreed to cancellation of an option granted on December 22, 2021, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 375 | Not disclosed Strike: $400.00 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 4 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 375 shares Expires 2031-02-03 F3 · price: The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 375 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 3 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375 Underlying: Common Stock · 375 shares Expires 2031-02-03 F3 · price: The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 1,236 | Not disclosed Strike: $86.80 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 2 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,236 shares Expires 2030-09-02 F2 · price: The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,236 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321149 · ownership.xml · derivative · entry 1 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,236 Underlying: Common Stock · 1,236 shares Expires 2030-09-02 F2 · price: The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 05, 2025 Filed Feb 4, 2026 16:32 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 125 | $4.61 | $575.88 |
DisclosureSEC source: 0001193125-26-037690 · ownership.xml · nonDerivative · entry 1 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,415 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan , in transactions that were exempt under Rule 16b-3(c). Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 19:19 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-250334 · ownership.xml · nonDerivative · entry 2 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,943 F2 · date: The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F3 · deemedExecutionDate: The restricted stock units subject to the award will vest in full on September 15, 2026, assuming continued employment through such date. F2 · price: The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| June 06, 2025 Filed Oct 24, 2025 19:19 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 125 | $5.49 | $686.50 |
DisclosureSEC source: 0001193125-25-250334 · ownership.xml · nonDerivative · entry 1 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 943 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan and therefore exempt under Rule 16b-3(c) Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:40 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 226,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0000950170-25-063846 · ownership.xml · derivative · entry 3 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,000 Underlying: Common Stock · 226,000 shares Expires 2035-04-30 F3 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025. Read SEC document |
| December 16, 2024 Filed May 5, 2025 20:40 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $0.50 | $1,241.25 |
DisclosureSEC source: 0000950170-25-063846 · ownership.xml · nonDerivative · entry 1 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,633 F1 · kind: and therefore exempt under Rule 16b-3(c) F2 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 17:17 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000950170-24-086136 · ownership.xml · derivative · entry 2 Nemec Sarah · CIK 0002023538 · VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-07-22 F2 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest on July 15, 2025. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 17:17 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000950170-24-086136 · ownership.xml · derivative · entry 1 Nemec Sarah · CIK 0002023538 · VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-07-22 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. Read SEC document |
| June 06, 2024 Filed May 5, 2025 20:40 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $0.64 | $1,593.50 |
DisclosureSEC source: 0000950170-25-063846 · ownership.xml · nonDerivative · entry 2 Nemec Sarah · CIK 0002023538 · Senior VP, Finance and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,863 F1 · kind: and therefore exempt under Rule 16b-3(c) F2 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.